Study S000821

The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06461377
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: RECRUITING
Enrollment: 50
Start: 2024-06-13
Primary completion: 2026-12-31
Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
Conditions: Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
Interventions: DRUG:Glucagon-like peptide-1 receptor agonist：Semaglutide
Results posted: FALSE

Registered primary outcomes

heart rate variability（HRV） [baseline and 12 weeks later]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012873	Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions. Mehta K, Current protein & peptide science	2021	Other trial	PMID 33292149 DOI	registry reference BACKGROUND:33292149
R0014959	Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro. Takaku S, International journal of molecular sciences	2021	Preclinical	PMID 33804063 DOI	registry reference BACKGROUND:33804063
R0026299	Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. Williams SM, Diabetes therapy : research, treatment and education of diabetes and related disorders	2019	Narrative review	PMID 31552598 DOI	registry reference BACKGROUND:31552598